2006, Drugs and Pharmaceuticals - Drug Discovery Digest

Latest CMS Data Reveal the Truth About U.S. Drug Spending

Drug Channels

FEBRUARY 7, 2024

As you will see, retail and mail prescription drug spending remain a consistently small share of the $4.5 And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices. Tomorrow, we’ll be treated to a Senate show trial featuring pharmaceutical company executives.

Pharmaceutical Companies

Pharmaceutical Companies Drugs Pharmaceuticals Trials

Drug Wholesalers and Brand-Name Drug Prices: Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s

Drug Channels

DECEMBER 5, 2023

Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Tomorrow on Drug Channels , I’ll delve into the pros and cons of this new approach. to 1:30 p.m.

Pharmacy

Pharmacy Drugs Hospitals Pharmaceuticals

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

Drug Channels

APRIL 8, 2024

I am pleased to announce the inaugural Drug Channels Leadership Forum ! The Leadership Forum will be an executive gathering where drug channel leaders can network and discuss key issues and challenges facing the commercial healthcare system. And of course, I'll be there to moderate the entire event and lead the fireside chats.

Pharmacy

Pharmacy Drugs Government Pharmaceuticals

What Pharmaceutical Manufacturers Value Most from a Hub

Drug Channels

SEPTEMBER 8, 2023

Nasir discusses how hubs help patients initiate and adhere to drug therapies. Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Therapies Production Research

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers

Drug Channels

OCTOBER 17, 2023

These financial firms have assembled significant oncology practice management companies that are primed for purchase by drug channel participants. Nonetheless, I expect this consolidation activity to continue—enabling a new round of vertical integration in the drug channel. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmaceuticals

Pharmaceuticals Hospitals Drugs

Phase I trial launches into oral drug for radioactive contamination

Drug Discovery World

MAY 17, 2023

A first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body has begun. The trial is testing the safety, tolerability and processing in the body of escalating doses of the investigational drug product HOPO 14-1 in healthy adults.

Trials

Trials International Clinical Trials DNA

Available for Preorder: The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

SEPTEMBER 20, 2022

On October 11, 2022, Drug Channels Institute will release The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Drugs

Three Digital Intake Strategies For Eliminating Patient Enrollment Forms

Drug Channels

MARCH 22, 2024

He then explains three ways that specialty pharmaceutical companies can use digital intake strategies to speed patient enrollment. To learn about AssistRx’s digital intake solutions, download Digital Intake for Specialty Drug Programs: Q1 2024 Progress Report. Read on for Adam’s insights.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Therapies Drugs

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

Drug Channels

APRIL 1, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription. Click here to see the original post from December 2023.

Pharmacy

Pharmacy Hospitals Pharmaceuticals Drugs

Four Ways for Field Teams to Tackle Drug Utilization Management and Optimize Patient Access

Drug Channels

MAY 18, 2023

To learn more about Phil’s access and commercialization solutions, download their free whitepaper, Modernize the Patient Access Experience: Transform Your Pharmaceutical Brand. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. You can also visit [link]. Read on for Patrick’s insights.

Drugs

Drugs Pharmaceuticals

What I (and Others) Told the Senate about the 340B Drug Pricing Program

Drug Channels

AUGUST 8, 2023

Click here to read the Drug Channels Institute letter to Senators Thune, Stabenow, Moore Capito, Baldwin, Moran, and Cardin. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. I shared my $0.02 How could I not?

Pharmacy

Pharmacy Hospitals Drugs Pharmaceuticals

How the Biosimilar Boom Boosts Drug Wholesalers’ Profits

Drug Channels

OCTOBER 18, 2022

The biosimilar boom for provider-administered drugs continues to accelerate. As we explain below, this accelerating adoption also boosts profits for pharmaceutical wholesalers and specialty distributors—particularly when these channel participants can influence which biosimilar version a provider utilizes. drug distribution.

Available for Preorder: The 2021-22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

SEPTEMBER 14, 2021

On October 5, 2021, Drug Channels Institute will release The 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. to 1:30 p.m.

Pharmaceuticals

Pharmaceuticals Marketing Drugs

The 340B Drug Pricing Program: Trends, Controversies, and Outlook (NEW Live Video Webinar)

Drug Channels

MAY 21, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.

Pharmacy

Pharmacy Drugs Pharmaceuticals Marketing

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us) (rerun)

Drug Channels

JULY 29, 2022

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. d/b/a Drug Channels Institute.

Pharmacy

Pharmacy Government Drugs Pharmaceuticals

Choosing the Right Hub Partner: A Blueprint for Decision-Makers

Drug Channels

JUNE 7, 2024

Nasir highlights manufacturers' top objectives and vendor metrics from CareMetx’s recent survey of leaders and decision makers in the specialty pharmaceutical industry. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Read on for Nasir’s insights.

Pharmaceuticals

Pharmaceuticals Production Drugs

NEW: The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

OCTOBER 11, 2022

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: U.S.

Pharmaceuticals

Pharmaceuticals Biosimilars Licensing Licensing

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs (rerun)

Drug Channels

APRIL 21, 2022

By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. The video is excerpted from my recent Drug Channels Update: Buy-and-Bill Trends video webinar.

Pharmacy

Pharmacy Drugs Pharmaceuticals Hospitals

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers (rerun)

Drug Channels

DECEMBER 14, 2023

This week, I’m rerunning some popular posts while I prepare for tomorrow’s Drug Channels Outlook 2024 live video webinar. These financial firms have assembled significant oncology practice management companies that are primed for purchase by drug channel participants. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmaceuticals

Pharmaceuticals Hospitals Drugs

A New JAMA Study Misleads About Drug Prices—And Launches a New Attack on Patients with Ultra-Rare Diseases

Drug Channels

JUNE 14, 2022

Last week, the authors of a new JAMA study claimed that “prices for new drugs are skyrocketing.” The authors obscure the real story with mathematical sleight-of-hand that misrepresents the underlying data and overlooks the true nature of today’s pharmaceutical innovations. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Disease

Disease Drugs Pharmaceuticals Treatment

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs

Drug Channels

OCTOBER 25, 2021

By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. The video is excerpted from my recent Drug Channels Update: Buy-and-Bill Trends video webinar.

Pharmacy

Pharmacy Drugs Pharmaceuticals Hospitals

White Bagging Update 2023: Saving Money or Shifting Costs? (rerun)

Drug Channels

DECEMBER 13, 2023

This week, I’m rerunning some popular posts while I prepare for Fiday's Drug Channels Outlook 2024 live video webinar. Time for our annual update on the channels for provider-administered drugs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Pharmaceuticals Production

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers (rerun)

Drug Channels

OCTOBER 4, 2023

This week, I’m rerunning some popular posts while I put the finishing touches on DCI's new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Drugs

Exclusive Report: Manufacturers Identify the Three Critical Drivers of Hub Success

Drug Channels

FEBRUARY 24, 2023

Matt shares three key findings from CareMetx’s exclusive new survey on patient support services for specialty pharmaceuticals. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Matt’s insights.

Pharmaceuticals

Pharmaceuticals Drugs

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations (rerun)

Drug Channels

OCTOBER 2, 2023

This week, I’m rerunning some popular posts while I put the finishing touches on DCI's new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Click here to see the original post from May 2023.

Pharmacy

Pharmacy Pharmaceuticals Marketing Drugs

New SingleCare Pharma Solutions Help Drugmakers Reach Cash-Paying Patients

Drug Channels

JULY 13, 2023

Today’s guest post comes from Josh Bliss, SVP of Customer Acquisition and Head of Pharma Solutions at SingleCare Josh discusses the challenges that pharmaceutical manufacturers face connecting with consumers who could benefit from patient financial support programs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmaceuticals

Pharmaceuticals Marketing Drugs

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us)

Drug Channels

APRIL 12, 2022

As you will see below, outpatient prescription drugs dispensed by retail and mail pharmacies are projected to remain a small share (8.4%) of total U.S. One bright spot: consumers will account for an ever-smaller share of drug spending. Thus, the government actuaries expect that pharmaceuticals will not be the key driver of U.S.

Pharmacy

Pharmacy Government Drugs Pharmaceuticals

White Bagging Update 2023: Saving Money or Shifting Costs?

Drug Channels

SEPTEMBER 13, 2023

Time for our annual update on the channels for provider-administered drugs. For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Pharmaceuticals Production

Still Not Skyrocketing: New CMS Data Reinforce the Truth About U.S. Drug Spending

Drug Channels

FEBRUARY 1, 2022

As you will see, outpatient drug spending remains a small—and shrinking—share of the $4.1 What's more, drug spending again grew more slowly than overall healthcare spending. Demonizing pharmaceuticals as a driver of U.S. Demonizing pharmaceuticals as a driver of U.S. d/b/a Drug Channels Institute. healthcare.

Hospitals

Hospitals Drugs Pharmaceuticals

Available for Preorder: The 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

SEPTEMBER 12, 2023

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Thank you for your interest in our work.

Pharmaceuticals

Pharmaceuticals Pharmacy Biosimilars Licensing

Building New Data Connections Helps Brands Lower Adherence

Drug Channels

OCTOBER 1, 2022

Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read on for Kylie’s insights.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Production Drugs

NEW: The 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

OCTOBER 5, 2021

I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. Twice a year, I spend my evenings and weekends writing two comprehensive, fact-based, and nonpartisan reports on drug channel economics.

Pharmaceuticals

Pharmaceuticals Biosimilars Licensing Licensing

Building New Data Connections Helps Brands Lower Adherence Barriers

Drug Channels

OCTOBER 1, 2022

Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read on for Kylie’s insights.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Production Drugs

Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: A 2022 Update

Drug Channels

OCTOBER 13, 2022

pharmaceutical distribution, payment, and reimbursement system. drug channels. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. But there are two slides that people seem to appreciate the most.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs

White Bagging Update 2022: Hospitals Battle to Boost Buy-and-Bill

Drug Channels

SEPTEMBER 21, 2022

In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. The battle for control of the specialty patient continues.

Specialty Pharmacies

Specialty Pharmacies Hospitals Pharmacy Pharmaceuticals

The Case for Data Unity, Sharing, and Usability

Drug Channels

JUNE 2, 2022

Bonnie describes how pharmaceutical care would benefit from standard medical record identification. To learn more, download the Wolters Kluwer free ebook: Drug Data Unity: Realistic and Idealistic Futures for Information Exchange. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Drugs

NOW AVAILABLE: The 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

OCTOBER 10, 2023

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: U.S.

Pharmaceuticals

Pharmaceuticals Specialty Pharmacies Pharmacy Biosimilars

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

Drug Channels

OCTOBER 3, 2023

This week, I’m rerunning some popular posts while I put the finishing touches on our new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Will payers let Humira go?

The Economics of Copay Accumulators, Maximizers, and Alternative Funding Programs (Video) (rerun)

Drug Channels

OCTOBER 5, 2023

This week, I’m rerunning some popular posts while I put the finishing touches on DCI's new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. In the video excerpt below, I describe these new approaches that plans offset specialty drug expenses. Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmaceuticals

Pharmaceuticals Marketing Drugs

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations

Drug Channels

MAY 24, 2023

In recent years, each of these companies has launched new group purchasing organizations (GPOs) to further consolidate the number of covered lives in rebate negotiations with pharmaceutical manufacturers. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. to 1:30 p.m.

Pharmacy

Pharmacy Pharmaceuticals Marketing Drugs

Improving Out-of-Pocket Cost Transparency For Physicians

Drug Channels

AUGUST 12, 2022

Divya then explains how GoodRx partners with pharmaceutical companies to improve cost transparency and communication between patients and providers. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Research Drugs

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers

Drug Channels

JUNE 13, 2023

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. to 1:30 p.m.

Pharmaceuticals

Pharmaceuticals Drugs

Four Solutions Manufacturers Should Consider For Retail and Specialty-lite Products

Drug Channels

APRIL 8, 2022

Michael discusses patient support challenges that are unique to specialty-lite pharmaceuticals. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Michael’s insights.

Specialty Pharmacies

Specialty Pharmacies Production Pharmacy Pharmaceuticals

Informa Connect's Life Sciences Commercial Contracts & Chargebacks 2022 Hybrid

Drug Channels

APRIL 11, 2022

Visit informaconnect.com/contracts-chargebacks to view the complete agenda, then register using the exclusive Drug Channels discount code 22DC10 to receive 10% off ! Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).

Science

Science Pharmaceuticals Drugs

Latest CMS Data Reveal the Truth About U.S. Drug Spending

Drug Wholesalers and Brand-Name Drug Prices: Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s

Trending Sources

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

What Pharmaceutical Manufacturers Value Most from a Hub

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers

Phase I trial launches into oral drug for radioactive contamination

Available for Preorder: The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Three Digital Intake Strategies For Eliminating Patient Enrollment Forms

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

Four Ways for Field Teams to Tackle Drug Utilization Management and Optimize Patient Access

What I (and Others) Told the Senate about the 340B Drug Pricing Program

How the Biosimilar Boom Boosts Drug Wholesalers’ Profits

Available for Preorder: The 2021-22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

The 340B Drug Pricing Program: Trends, Controversies, and Outlook (NEW Live Video Webinar)

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us) (rerun)

Choosing the Right Hub Partner: A Blueprint for Decision-Makers

NEW: The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs (rerun)

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers (rerun)

A New JAMA Study Misleads About Drug Prices—And Launches a New Attack on Patients with Ultra-Rare Diseases

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs

White Bagging Update 2023: Saving Money or Shifting Costs? (rerun)

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers (rerun)

Exclusive Report: Manufacturers Identify the Three Critical Drivers of Hub Success

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations (rerun)

New SingleCare Pharma Solutions Help Drugmakers Reach Cash-Paying Patients

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us)

White Bagging Update 2023: Saving Money or Shifting Costs?

Still Not Skyrocketing: New CMS Data Reinforce the Truth About U.S. Drug Spending

Available for Preorder: The 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Building New Data Connections Helps Brands Lower Adherence

NEW: The 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Building New Data Connections Helps Brands Lower Adherence Barriers

Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: A 2022 Update

White Bagging Update 2022: Hospitals Battle to Boost Buy-and-Bill

The Case for Data Unity, Sharing, and Usability

NOW AVAILABLE: The 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

The Economics of Copay Accumulators, Maximizers, and Alternative Funding Programs (Video) (rerun)

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations

Improving Out-of-Pocket Cost Transparency For Physicians

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers

Four Solutions Manufacturers Should Consider For Retail and Specialty-lite Products

Informa Connect's Life Sciences Commercial Contracts & Chargebacks 2022 Hybrid

Stay Connected